Mette Ilander

Mette Ilander

Auto-generated profile, based on publicly available information

Mette Ilander

University of Helsinki 1 Hematology Research Unit Helsinki, Helsinki University Hospital Comprehensive Cancer Center Helsinki, Finland

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
OBOscar Brück
Oscar Brück
ODOlli Dufva
Olli Dufva
HHHelena Hohtari
Helena Hohtari
SBSami Blom
Sami Blom
RTRiku Turkki
Riku Turkki
SMSatu Mustjoki
Satu Mustjoki
The immunologic microenvironment in various solid tumors is aberrant and correlates with clinical survival. Here, we present a comprehensive analysis of the immune environment of acute myeloid leukemia (AML) bone marrow (BM) at diagnosis. We compared the immunologic landscape of formalin-fixed paraffin-embedded BM trephine samples from AML (n = 69), chronic myeloid leukemia (CML; n = 56), and B-cell acute lymphoblastic leukemia (B-ALL) patients (n = 52) at diagnosis to controls (n = 12) with 30 immunophenotype markers using multiplex immunohistochemistry and computerized image analysis. We identified distinct immunologic profiles specific for leukemia subtypes and controls enabling accurate classification of AML (area under the curve [AUC] = 1.0), CML (AUC = 0.99), B-ALL (AUC = 0.96), and control subjects (AUC = 1.0). Interestingly, 2 major immunologic AML clusters differing in age, T-cell receptor clonality, and survival were discovered. A low proportion of regulatory T cells and pSTAT1+cMAF− monocytes were identified as novel biomarkers of superior event-free survival in intensively treated AML patients. Moreover, we demonstrated that AML BM and peripheral blood samples are dissimilar in terms of immune cell phenotypes. To conclude, our study shows that the immunologic landscape considerably varies by leukemia subtype suggesting disease-specific immunoregulation. Furthermore, the association of the AML immune microenvironment with clinical parameters suggests a rationale for including immunologic parameters to improve disease classification or even patient risk stratification.

31 January 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MIMette Ilander
Mette Ilander
AKAnna Kreutzman
Anna Kreutzman
PRPeter Rohon
Peter Rohon
TMThatianat Corrêa Melo
Thatianat Corrêa Melo
EFEdgar Faber
Edgar Faber
SMSatu Mustjoki
Satu Mustjoki
A small proportion of chronic myeloid leukemia patients treated with interferon-α (IFN-α) monotherapy are able to discontinue the treatment without disease relapse although residual leukemia cells are present. Recently, we showed that these patients have increased amount of NK-cells and a distinct blood cytokine profile. We now aimed to study the function of NK- and T-cells in order to understand the role of the immune system in maintaining the treatment response after IFN-α discontinuation. The study included 13 patients: 5 patients were still treated with IFN-α monotherapy (IFN-ON, median treatment time 163 months) and 8 had stopped the treatment successfully (IFN-OFF, median time without therapy 42 months). Detailed immunophenotype and cytokine production of NK- and T-cells was analyzed with flow cytometry. In addition, the cytotoxicity of NK-cells was studied using K562 as target cells and both the degranulation and direct killing was measured. Compared to healthy controls, IFN-OFF patients had increased proportion of CD4+ effector memory (CCR7−CD45RA−; median 23% vs. healthy 16%, p = 0.009) and CD8+ central memory T-cells (CCR7+CD45RA−; median 26% vs. healthy 14%, p = 0.004). Further, upon stimulation the IFN-γ/TNF-α cytokine secretion by CD4+ T-cells was significantly enhanced in IFN-OFF patients (median 13.7% vs. healthy 7.8%, p = 0.01), and CD4+ effector and central memory cells were the main cytokine producers. No similar increase was observed in IFN-ON group (6.5%). In addition, the proportion of NK-cells was significantly increased in IFN-OFF patients (median IFN-OFF 24%, healthy 13%, p = 0.04), but their direct killing of K562 cells was impaired. The cytotoxicity of NK-cells was also diminished in IFN-ON patients. To conclude, in addition to elevated NK-cell count, IFN-OFF patients have increased amount of memory T-cells, which are able to induce strong cytokine response upon stimulation. This activity may contribute to the maintenance of prolonged remission after successful IFN-α discontinuation.

8 February 2020 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
HKHenna Kasanen
Henna Kasanen
MHMicaela Hernberg
Micaela Hernberg
SMSiru Mäkelä
Siru Mäkelä
OBOscar Brück
Oscar Brück
SJSusanna Juteau
Susanna Juteau
AKAnna Kreutzman
Anna Kreutzman
Anti-PD1 treatment has improved the survival of metastatic melanoma patients, yet it is unknown which patients benefit from the treatment. In this exploratory study, we aimed to understand the effects of anti-PD1 therapy on the patients’ immune system and discover the characteristics that would result in successful treatment. We collected peripheral blood (PB) samples from 17 immuno-oncology-naïve metastatic melanoma patients before and after 1 and 3 months of anti-PD1 therapy. In addition, matching tumor biopsies at the time of diagnosis were collected for tissue microarray. The complete blood counts, PB immunophenotype, serum cytokine profiles, and tumor-infiltrating lymphocytes were analyzed and correlated with the clinical data. Patients were categorized based on their disease control into responders (complete response, partial response, stable disease > 6 months, N = 11) and non-responders (progressive disease, stable disease ≤ 6 months, N = 6). During therapy, the PB natural killer T (NKT) cell frequency, expression of CD25 and CD45RO on cytotoxic natural killer (NK) cells, and serum CXC chemokine levels were significantly increased in responders. Furthermore, higher age together with age-associated characteristics from PB, lower frequency of PB-naïve CD8+ T cells, and elevated levels of serum MCP-4 and OPG were discovered as baseline predictors of treatment response. We therefore propose that in addition to T cells, anti-PD1 treatment is associated with NK- and NKT-cell population dynamics, and that the age-associated characteristics from PB together with older age may contribute to prolonged PFS in anti-PD1-treated melanoma patients.

3 November 2017 in Oncotarget
Verified
Journal Article
Open access
MIMette Ilander
Mette Ilander
SMSatu Mustjoki
Satu Mustjoki

14 August 2026 in Cancer Immunology Research
Verified
Journal Article
Open access
JHJani Huuhtanen
Jani Huuhtanen
SFSofia Forstén
Sofia Forstén
BFBrittany Ford
Brittany Ford
JSJohannes Smolander
Johannes Smolander
OBOscar Brück
Oscar Brück
SMSatu Mustjoki
Satu Mustjoki
Occasional complete responses (CR) to immune checkpoint inhibitor therapy demonstrate that acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) can be immunosensitive when appropriately targeted. In this study, we analyzed patients with AML/MDS (n = 14) who were treated with the anti-TIM3 sabatolimab and the hypomethylating agent decitabine in a phase Ib clinical trial (NCT03066648) using single-cell RNA and T-cell receptor (TCR) sequencing (n = 6) and functional coculture assays. Unlike T cell–restricted CTLA4 and PD1, TIM3 was broadly expressed across natural killer (NK) cell, myeloid cell, and T-cell populations. Therapy induced the expansion of cytotoxic NK cell subsets and enhanced type I IFN signaling. Fewer than 1% of bone marrow CD8+ T cells displayed a canonical exhaustion phenotype, and treatment preferably expanded small CD8+ T-cell clones in responders. Responders exhibited greater expansion of cytotoxic CD4+ T cells and B cells, as exemplified by a patient with preexisting CD4+ T-cell large granular lymphocyte leukemia (T-LGLL) achieving an outstanding CR lasting 23 months. More than 20% of this patient’s lymphocytes were T-LGLL cells expressing a TCR capable of recognizing autologous blasts. Overall, our results suggest that anti-TIM3 combined with decitabine engages a distinct mechanism of immune activation compared with anti–PD-1 and anti-CTLA4, preferentially expanding NK cell and CD4+ T-cell populations.